196 related articles for article (PubMed ID: 32722909)
1. Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent.
Cheng J; Fuller J; Feldman R; Tap W; Owa T; Fuks Z; Kolesnick R
Cell Physiol Biochem; 2020 Jul; 54(4):707-718. PubMed ID: 32722909
[TBL] [Abstract][Full Text] [Related]
2. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery.
Truman JP; García-Barros M; Kaag M; Hambardzumyan D; Stancevic B; Chan M; Fuks Z; Kolesnick R; Haimovitz-Friedman A
PLoS One; 2010 Aug; 5(8):e12310. PubMed ID: 20808818
[TBL] [Abstract][Full Text] [Related]
3. Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery.
Truman JP; García-Barros M; Kaag M; Hambardzumyan D; Stancevic B; Chan M; Fuks Z; Kolesnick R; Haimovitz-Friedman A
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20941382
[TBL] [Abstract][Full Text] [Related]
4. Targeting acid sphingomyelinase with anti-angiogenic chemotherapy.
Jacobi J; García-Barros M; Rao S; Rotolo JA; Thompson C; Mizrachi A; Feldman R; Manova K; Bielawska A; Bielawska J; Fuks Z; Kolesnick R; Haimovitz-Friedman A
Cell Signal; 2017 Jan; 29():52-61. PubMed ID: 27702691
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
6. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.
Verschraegen CF; Arias-Pulido H; Lee SJ; Movva S; Cerilli LA; Eberhardt S; Schmit B; Quinn R; Muller CY; Rabinowitz I; Purdy M; Snyder D; Bocklage T
Ann Oncol; 2012 Mar; 23(3):785-790. PubMed ID: 21746804
[TBL] [Abstract][Full Text] [Related]
7. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation.
van Hell AJ; Haimovitz-Friedman A; Fuks Z; Tap WD; Kolesnick R
Cell Signal; 2017 Jun; 34():86-91. PubMed ID: 28238856
[TBL] [Abstract][Full Text] [Related]
9. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model.
Zhou S; Yang Y; Yang Y; Tao H; Li D; Zhang J; Jiang G; Fang J
PLoS One; 2013; 8(7):e68589. PubMed ID: 23874680
[TBL] [Abstract][Full Text] [Related]
11. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
12. [Antiangionic drugs in soft tissue sarcoma].
Salas S; Huynh T; Deville JL; Duffaud F
Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
[TBL] [Abstract][Full Text] [Related]
13. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Ma L; Francia G; Viloria-Petit A; Hicklin DJ; du Manoir J; Rak J; Kerbel RS
Cancer Res; 2005 Jun; 65(12):5365-73. PubMed ID: 15958585
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
Casneuf VF; Demetter P; Boterberg T; Delrue L; Peeters M; Van Damme N
Oncol Rep; 2009 Jul; 22(1):105-13. PubMed ID: 19513511
[TBL] [Abstract][Full Text] [Related]
15. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
[TBL] [Abstract][Full Text] [Related]
16. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
17. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
18. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
[TBL] [Abstract][Full Text] [Related]
19. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.
Noguchi R; Yoshiji H; Ikenaka Y; Namisaki T; Kitade M; Kaji K; Yoshii J; Yanase K; Yamazaki M; Tsujimoto T; Kawaratani H; Fukui H
Oncol Rep; 2009 Aug; 22(2):355-60. PubMed ID: 19578777
[TBL] [Abstract][Full Text] [Related]
20. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Van Tine BA; Trent JC
Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
